Cargando…

What are the benefits of cognitive enhancers for Alzheimer's Disease: use of Population Impact Measures

BACKGROUND: The study aims to quantify the population impact of prescribing cholinesterase inhibitors to slow the cognitive decline in Alzheimer's disease (AD), and to compare with the benefit of treating hypertension to prevent the onset of AD. METHODS: Literature review to ascertain the preva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gammanpila, Udaya P, Burns, Alistair, Heller, Richard F, Purandare, Nitin
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206022/ https://www.ncbi.nlm.nih.gov/pubmed/17986333 http://dx.doi.org/10.1186/1471-2318-7-25

Ejemplares similares

Peripheral inflammatory markers in amnestic mild cognitive impairment
por: Karim, Salman, et al.
Publicado: (2014)

Treatment of cognitive impairment in Alzheimer's disease
por: Burns, Alistair
Publicado: (2003)

Diagnosis and management of Alzheimer's disease
por: Burns, Alistair
Publicado: (2000)

Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
por: Geifman, Nophar, et al.
Publicado: (2017)

Implementing guidelines in primary care: can population impact measures help?
por: Heller, Richard F, et al.
Publicado: (2003)

Prevention of dementia: Role of vascular risk factors and cerebral emboli
por: Purandare, Nitin
Publicado: (2009)

Vitamin D, Cognition and Alzheimer’s Disease: The Therapeutic Benefit is in the D-Tails
por: Landel, Véréna, et al.
Publicado: (2016)

Helping to prioritise interventions for depression and schizophrenia: use of Population Impact Measures
por: Heller, Richard F, et al.
Publicado: (2006)

What are the Benefits of Interacting with Nature?
por: Keniger, Lucy E., et al.
Publicado: (2013)

The Link between Cognitive Measures and ADLs and IADL Functioning in Mild Alzheimer's: What Has Gender Got to Do with It?
por: Hall, James R., et al.
Publicado: (2011)

Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease
por: Shineman, Diana W, et al.
Publicado: (2013)

A Novel Neurotrophic Drug for Cognitive Enhancement and Alzheimer's Disease
por: Chen, Qi, et al.
Publicado: (2011)

Methods and Benefits of Measuring Human-Centered Design in Global Health
por: Heller, Cheryl, et al.
Publicado: (2021)

Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?
por: Laurent, Cyril, et al.
Publicado: (2018)

What is the impact of ongoing statin use on cognitive decline and dementia progression in older adults with mild-moderate Alzheimer disease?
por: Murphy, Claire, et al.
Publicado: (2023)

Measuring cognition and function in the preclinical stage of Alzheimer's disease
por: Weintraub, Sandra, et al.
Publicado: (2018)

The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
por: Langbaum, Jessica B., et al.
Publicado: (2020)

What would be the benefits of a collaboration between psychoanalysis and cognitive neuroscience? The opinion of a neuroscientist
por: Ruby, Perrine
Publicado: (2013)

Status of Metabolomic Measurement for Insights in Alzheimer’s Disease Progression—What Is Missing?
por: Yin, Chunyuan, et al.
Publicado: (2023)

Leveraging Population Health Expertise to Enhance Community Benefit
por: Kaplan, Sue A., et al.
Publicado: (2020)

Prioritising between direct observation of therapy and case-finding interventions for tuberculosis: use of population impact measures
por: Heller, Richard F, et al.
Publicado: (2006)

Benefits of dietary polyphenols in Alzheimer’s disease
por: El Gaamouch, Farida, et al.
Publicado: (2022)

To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?
por: Caro, Jaime, et al.
Publicado: (2002)

What are the neural correlates of meta-cognition and anosognosia in Alzheimer's disease? A systematic review
por: Hallam, Brendan, et al.
Publicado: (2020)

The cognitive dysfunction related to Alzheimer disease or cerebral small vessel disease: What's the differences
por: Liang, Zhenhong, et al.
Publicado: (2021)

What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
por: Wallin, Anders, et al.
Publicado: (2022)

Unpicking the Semantic Impairment in Alzheimer’s Disease: Qualitative Changes with Disease Severity
por: Corbett, Faye, et al.
Publicado: (2012)

Impact of atrial fibrillation on the cognitive decline in Alzheimer’s disease
por: Nakase, Taizen, et al.
Publicado: (2023)

Static and Dynamic Cognitive Reserve Proxy Measures: Interactions with Alzheimer’s Disease Neuropathology and Cognition
por: Malek-Ahmadi, Michael, et al.
Publicado: (2017)

Impact of cognitive reserve on the progression of mild cognitive impairment to Alzheimer's disease in Japan
por: Osone, Akira, et al.
Publicado: (2015)

Polygenic risk scores for Alzheimer’s disease, and academic achievement, cognitive and behavioural measures in children from the general population
por: Korologou-Linden, Roxanna, et al.
Publicado: (2019)

Testing the Cognitive Reserve Index Questionnaire in an Alzheimer’s Disease Population
por: Garba, Asabe E., et al.
Publicado: (2020)

Telemedicine and cardiac implants: what is the benefit?
por: Varma, Niraj, et al.
Publicado: (2013)

Adaptive enrichment trials: What are the benefits?
por: Burnett, Thomas, et al.
Publicado: (2020)

Biomarkers to Measure Treatment Effects in Alzheimer's Disease: What Should We Look for?
por: Rockwood, Kenneth
Publicado: (2011)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease
por: Schultz, Stephanie A., et al.
Publicado: (2023)

Thirty-Five Years of Computerized Cognitive Assessment of Aging—Where Are We Now?
por: Sternin, Avital, et al.
Publicado: (2019)

Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer’s disease
por: Chow, Tiffany W, et al.
Publicado: (2007)

The Potential Benefits of Nanotechnology in Treating Alzheimer's Disease
por: Ling, Tan Sook, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_knapkage827eva586jqheh8ul1